Get notified when ENSC files again. Create a free account and we'll email you the moment its next filing is analyzed.
Get filing alertsRed Flags Detected
- Going Concern (new) — The auditor's report includes an explanatory paragraph stating substantial doubt about the company's ability to continue as a going concern.
Ensysce Biosciences prices $1.0M offering of 239,594 shares at $3.49, plus pre-funded warrants and private placement warrants
Filed March 31, 2025 · ~1 min read
Key Changes
-
high
Ensysce is offering 239,594 common shares at $3.49 and 75,594 pre-funded warrants at $3.4899, with concurrent private placement warrants for 630,376 shares at $3.24.
The Offering verify on EDGAR → -
high
The company expects gross proceeds of about $1.0 million and net proceeds of about $0.9 million after fees and expenses.
Use of Proceeds verify on EDGAR → -
medium
Net proceeds will fund general corporate purposes, including clinical trials for lead products and working capital.
Use of Proceeds verify on EDGAR →
4 more material changes behind this preview — plus the full narrative summary, section-by-section diffs against the prior filing, and verbatim quotes with EDGAR citations.
Want to see a complete report first? Today's free report (FPS 10-K) is open in full — no account needed.
Partner
Trade ENSC commission-free
Open an account, get a free stock.
Investing involves risk. Free stock terms apply.
Thanks — your feedback helps us improve report quality.
Figures/quotes linked to EDGAR · Narrative written by AI · Sep 3, 2026 · How we verify